These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 31378985)

  • 1. Review article: immune checkpoint inhibitors and the liver, from therapeutic efficacy to side effects.
    Lombardi A; Mondelli MU
    Aliment Pharmacol Ther; 2019 Oct; 50(8):872-884. PubMed ID: 31378985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges.
    Liu X; Qin S
    Oncologist; 2019 Feb; 24(Suppl 1):S3-S10. PubMed ID: 30819826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Setting the scene - a future 'epidemic' of immune-related adverse events in association with checkpoint inhibitor therapy.
    Bermudez MV; Papa S
    Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii1-vii6. PubMed ID: 31816083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint inhibitors: a narrative review of considerations for the anaesthesiologist.
    Lewis AL; Chaft J; Girotra M; Fischer GW
    Br J Anaesth; 2020 Mar; 124(3):251-260. PubMed ID: 32007241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint therapy in liver cancer.
    Xu F; Jin T; Zhu Y; Dai C
    J Exp Clin Cancer Res; 2018 May; 37(1):110. PubMed ID: 29843754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunostimulatory monoclonal antibodies for hepatocellular carcinoma therapy. Trends and perspectives.
    Mazzolini GD; Malvicini M
    Medicina (B Aires); 2018; 78(1):29-32. PubMed ID: 29360073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of hospitalizations among patients receiving immune checkpoint inhibitors at a community teaching hospital.
    Rasor B; Henderson R; Chan K
    J Oncol Pharm Pract; 2020 Jan; 26(1):60-66. PubMed ID: 30924739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hepatotoxicity associated with tumor immune checkpoint inhibitors].
    Lei XH; Tang YY; Li J; Mao YM
    Zhonghua Gan Zang Bing Za Zhi; 2020 Feb; 28(2):175-178. PubMed ID: 32164073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview.
    Plachouri KM; Vryzaki E; Georgiou S
    Curr Drug Saf; 2019; 14(1):14-20. PubMed ID: 30058498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Immunotherapy is cancer treatment with a novel side-effect profile].
    Kondrup M; Raunkilde L; Svane IM; Schmidt H; Bastholt L
    Ugeskr Laeger; 2017 Oct; 179(40):. PubMed ID: 28992844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond.
    Lee YH; Tai D; Yip C; Choo SP; Chew V
    Front Immunol; 2020; 11():568759. PubMed ID: 33117354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.
    Martins F; Sofiya L; Sykiotis GP; Lamine F; Maillard M; Fraga M; Shabafrouz K; Ribi C; Cairoli A; Guex-Crosier Y; Kuntzer T; Michielin O; Peters S; Coukos G; Spertini F; Thompson JA; Obeid M
    Nat Rev Clin Oncol; 2019 Sep; 16(9):563-580. PubMed ID: 31092901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-1 inhibitors monotherapy in hepatocellular carcinoma: Meta-analysis and systematic review.
    Voutsadakis IA
    Hepatobiliary Pancreat Dis Int; 2019 Dec; 18(6):505-510. PubMed ID: 31551142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immune checkpoint inhibitors in the treatment and management of hepatocellular carcinoma-related adverse reactions].
    Li ZC; Ren ZG
    Zhonghua Gan Zang Bing Za Zhi; 2021 Jun; 29(6):600-603. PubMed ID: 34225439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets.
    Neureiter D; Stintzing S; Kiesslich T; Ocker M
    World J Gastroenterol; 2019 Jul; 25(25):3136-3150. PubMed ID: 31333307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immuno-oncology for Hepatocellular Carcinoma: The Present and the Future.
    Armstrong SA; He AR
    Clin Liver Dis; 2020 Nov; 24(4):739-753. PubMed ID: 33012456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update.
    Nagai H; Muto M
    Int J Clin Oncol; 2018 Jun; 23(3):410-420. PubMed ID: 29516216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocellular Carcinoma Immunotherapy and the Potential Influence of Gut Microbiome.
    Temraz S; Nassar F; Kreidieh F; Mukherji D; Shamseddine A; Nasr R
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors.
    Weinmann SC; Pisetsky DS
    Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii59-vii67. PubMed ID: 31816080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and Management of Immune-Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors.
    Kottschade LA
    Curr Oncol Rep; 2018 Mar; 20(3):24. PubMed ID: 29511902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.